We are celebrating the 10th anniversary of the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary. On this occasion, a ceremony was held on site at the SRIMC in Budapest, bringing together several members of the Hungarian Government and representatives of the Servier group.
We concentrate a significant part of our research and drug discovery activities in Hungary. Located in the heart of the Budapest science park, SRMIC has 60 highly qualified employees, half of whom have a PhD degree. Led by Andras Kotschy, the Institute focuses its work on highly unmet medical needs such as oncology. Over the past 10 years, the research conducted by the SRIMC has led to breakthrough discoveries, particularly in oncology: two drug candidates discovered in this field have recently entered the clinical research phase, while a third has just entered the preclinical development stage.
The Institute also plays an important role in promoting scientific innovation in Hungary. Through its academic network, it fosters active relationships with the leading research centres and scientists in the region. The Servier Research Institute’s participation in the Center for University-Industry Cooperation (FIEK) on biomarkers, which it won in 2017 under the direction of Eötvös Loránd University, testifies to its commitment to quality, innovative and interdisciplinary research. This consortium promotes Servier’s activities in Medicinal Chemistry and also paves the way for future collaborations between the Group’s other research areas and Hungarian academic research groups.
“The Servier Research Institute of Medicinal Chemistry illustrates the Group’s commitment to Hungarian research,” says Andras Kotschy, Director of SRIMC. “Over the past 10 years, the Institute has established a constructive and trustworthy working relationship with Servier Group’s research units in France and Hungary, as well as with the Group’s partners, such as Novartis or Vernalis.”
We have been present for 25 years in Hungary, a strategic country for the Group. With more than 3,200 employees and 4 business units, Servier is a major player in the Hungarian pharmaceutical industry. It is the only country outside France that includes all the Group’s activities: Original research (SRIMC), clinical studies (Therapeutic Research Centre – ICTR), distribution of brand drugs (Servier Hungaria) as well as the research, development, production, and distribution of generic drugs (EGIS). These four activities serve only one purpose: to develop ever more effective treatments to better meet patients’ needs.
“Hungary’s high level of research excellence has led us to invest in the country on a sustainable basis. It is in line with our desire to carry out high-level research to find ever more innovative solutions for patients,” commented O. Laureau, President of Servier.
Several products from Servier’s main key research fields – diabetes, cardiovascular or neuropsychiatric diseases – have a leading position on the Hungarian market. Today, Servier focuses on oncology, an increasingly targeted and focused battle that brings hope to patients. This is reflected in an increase of the share of oncology in R&D investments in this field, which rose from 14% in 2015 to 37% in 2017 and should reach 50% by 2020, the number of programs in its portfolio devoted to it – 12 out of 37 – and the recent acquisition of the oncology branch of Shire Laboratory. Hungary currently has 4 innovative drugs on the market, in different types of cancers, but with limited access for patients. Servier would like all Hungarian patients who need these treatments to be able to access them quickly.
Resolutely anchored in Hungary, Servier continues to develop its activities locally through significant annual investments in fundamental and clinical research. As an example, the Budapest Therapeutic Research Centre has been strengthened to coordinate, from the Hungarian capital, all activities in South-East Europe.